Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease

Oliviero Olivieri; Antonella Bassi; Chiara Stranieri; Elisabetta Trabetti; Nicola Martinelli; Francesca Pizzolo; Domenico Girelli; Simonetta Friso; Pier Franco Pignatti; Roberto Corrocher

Journal of Lipid Research (Dec 2003)

Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease

Oliviero Olivieri,
Antonella Bassi,
Chiara Stranieri,
Elisabetta Trabetti,
Nicola Martinelli,
Francesca Pizzolo,
Domenico Girelli,
Simonetta Friso,
Pier Franco Pignatti,
Roberto Corrocher

Affiliations

Oliviero Olivieri: Unit of Internal Medicine, Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy; Institute of Clinical Chemistry, University of Verona, Verona, Italy; Section of Biology and Genetics, Department of Mother and Child and Biology–Genetics, University of Verona, Verona, Italy
Antonella Bassi: Unit of Internal Medicine, Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy; Institute of Clinical Chemistry, University of Verona, Verona, Italy; Section of Biology and Genetics, Department of Mother and Child and Biology–Genetics, University of Verona, Verona, Italy
Chiara Stranieri: Unit of Internal Medicine, Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy; Institute of Clinical Chemistry, University of Verona, Verona, Italy; Section of Biology and Genetics, Department of Mother and Child and Biology–Genetics, University of Verona, Verona, Italy
Elisabetta Trabetti: Unit of Internal Medicine, Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy; Institute of Clinical Chemistry, University of Verona, Verona, Italy; Section of Biology and Genetics, Department of Mother and Child and Biology–Genetics, University of Verona, Verona, Italy
Nicola Martinelli: Unit of Internal Medicine, Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy; Institute of Clinical Chemistry, University of Verona, Verona, Italy; Section of Biology and Genetics, Department of Mother and Child and Biology–Genetics, University of Verona, Verona, Italy
Francesca Pizzolo: Unit of Internal Medicine, Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy; Institute of Clinical Chemistry, University of Verona, Verona, Italy; Section of Biology and Genetics, Department of Mother and Child and Biology–Genetics, University of Verona, Verona, Italy
Domenico Girelli: Unit of Internal Medicine, Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy; Institute of Clinical Chemistry, University of Verona, Verona, Italy; Section of Biology and Genetics, Department of Mother and Child and Biology–Genetics, University of Verona, Verona, Italy
Simonetta Friso: Unit of Internal Medicine, Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy; Institute of Clinical Chemistry, University of Verona, Verona, Italy; Section of Biology and Genetics, Department of Mother and Child and Biology–Genetics, University of Verona, Verona, Italy
Pier Franco Pignatti: Unit of Internal Medicine, Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy; Institute of Clinical Chemistry, University of Verona, Verona, Italy; Section of Biology and Genetics, Department of Mother and Child and Biology–Genetics, University of Verona, Verona, Italy
Roberto Corrocher: Unit of Internal Medicine, Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy; Institute of Clinical Chemistry, University of Verona, Verona, Italy; Section of Biology and Genetics, Department of Mother and Child and Biology–Genetics, University of Verona, Verona, Italy

Journal volume & issue: Vol. 44, no. 12
pp. 2374 – 2381

Abstract

Read online

Apolipoprotein C-III (apoC-III) is a marker of triglyceride (TG)-rich lipoproteins, which are often increased in metabolic syndrome (MS). The T−455C polymorphism in the insulin-responsive element of the APOC3 gene influences TG and apoC-III levels. To evaluate the contribution of apoC-III levels and T−455C polymorphisms in the coronary artery disease (CAD) risk of MS patients, we studied 873 patients, 549 with CAD and 251 with normal coronary arteries. Patients were classified also as having or not having MS (MS, n = 270; MS-free, n = 603). Lipids, insulin, apolipoprotein levels, and APOC3 T−455C genotypes were evaluated. ApoC-III levels were significantly increased in MS patients, and the probability of having MS was correlated with increasing quartiles of apoC-III levels. MS patients with CAD had significantly higher apoC-III levels than did CAD-free MS patients. The carriership for the −455C variant multiplied the probability of CAD in MS in an allele-specific way and was associated with increased apoC-III and TG levels. Obesity was less frequent in MS carriers of the −455C allele than in MS noncarriers (21.6% vs. 34.8%, P < 0.05).In conclusion, apoC-III-rich lipoprotein metabolism and the APOC3 polymorphism have relevant impacts on the CAD risk of MS patents.

Published in Journal of Lipid Research

ISSN: 0022-2275 (Print); 1539-7262 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science: Chemistry: Organic chemistry: Biochemistry
Website: https://www.journals.elsevier.com/journal-of-lipid-research

About the journal

Abstract

Keywords